4.3 Solid Organ Transplant & HLA Crossmatching

4.3 Solid Organ Transplant & HLA Crossmatch

Crossmatching asks whether the recipient has preformed antibody that would bind donor HLA and threaten the graft. The flow cytometer is central to both cell-based crossmatch and the antibody-specificity mapping that powers virtual crossmatching.

CDC (Complement-Dependent Cytotoxicity) Crossmatch

Recipient serum is incubated with donor lymphocytes (T cells, B cells, or both). If cytotoxic anti-donor HLA antibody is present, it binds donor cells and activates complement, lysing them; a viability dye (e.g., eosin, trypan, or acridine orange/ethidium) counts dead cells.

• T-cell CDC detects class I antibodies; B-cell CDC detects class I and class II (B cells carry both) but is less specific because B cells express more Fc receptors and can give false positives.
• A DTI (dithiothreitol) crossmatch distinguishes IgM (reduced by DTT, clinically less relevant) from IgG (persistent, clinically significant).
• CDC misses low-titer antibodies because complement activation has a detection floor.

Flow Crossmatch

The flow cytometric crossmatch is more sensitive than CDC. Donor lymphocytes are incubated with recipient serum, then stained with anti-human IgG (often a PE- or FITC-conjugated F(ab')2 anti-IgG) plus lineage markers to gate T and B cells (CD3, CD19). Results are reported as MFI of the bound IgG channel relative to a negative-control serum.

Flow crossmatch detects antibodies that fail to fix complement and thus are missed by CDC, and it is more quantitative. It is the standard for sensitized kidney-transplant candidates. A channel ratio or normalized MFI above the laboratory threshold is reported as positive.

Luminex Single-Antigen Beads and Virtual Crossmatch

Luminex single-antigen beads (SAB) display individual HLA alleles on separate bead classes. Recipient serum is incubated with the panel; MFI per bead reports antibody reactivity against each specificity. This produces the recipient's anti-HLA antibody profile (often summarized as calculated PRA, cPRA).

• Virtual crossmatch compares the recipient's antibody specificity (from SAB) against the donor's typed HLA antigens — no donor-recipient cell mixing required. An unacceptable-antigen list (antibodies above an MFI threshold) is set per center.
• A positive virtual crossmatch predicts a positive cell-based crossmatch and is used to decline organs prospectively.
• cPRA estimates the fraction of donors against whom a recipient would be crossmatch-positive, guiding organ allocation priority.

Post-Transplant DSA Monitoring

After transplant, donor-specific antibody (DSA) is monitored with the same SAB platform, restricted to the donor's antigens. De novo DSA, especially class II (DQ), is a strong predictor of antibody-mediated rejection (ABMR). Rising DSA MFI triggers biopsy and consideration of desensitization. Complement-binding assays (C1q, C3d) further stratify DSA by pathogenicity.

Worked Example: cPRA and Virtual Crossmatch

A candidate's Luminex single-antigen bead panel shows MFI above the center's unacceptable-antigen threshold (e.g., 1000 MFI) for HLA-A2, HLA-B44, and HLA-DQ7. The candidate's cPRA — the percent of a reference donor population carrying at least one of these unacceptable antigens — is reported by the allocation system; a cPRA of 80% means roughly 80% of donors would be crossmatch-positive and only 20% are compatible. When a donor organ is offered, the donor's HLA typing (say A2/A24, B35/B44, DR4/DR7) is compared with the candidate's unacceptable list: A2 and B44 are both unacceptable, so the virtual crossmatch is positive, and the organ is declined without a cell-based crossmatch. This saves the time and cells a CDC or flow crossmatch would consume and keeps the organ in the allocation pool for compatible recipients.

Sensitivity Hierarchy in Practice

CDC detects only complement-fixing IgG at moderate-to-high titer; flow crossmatch detects lower-titer and non-complement-fixing IgG; Luminex SAB detects the lowest-titer antibodies and resolves their specificity. A patient can be CDC-negative, flow-positive, and SAB-positive for the same specificity — the more sensitive the method, the earlier an antibody is detected. Clinical decisions weight these layers: a CDC-positive crossmatch is usually a contraindication to transplant, whereas an SAB-only DSA may permit transplant with post-transplant monitoring.

Exam Traps

• B-cell crossmatch is less specific than T-cell crossmatch (B cells express Fc receptors, carry both class I/II, and can yield false positives).
• DTT destroys IgM but not IgG; a DTT crossmatch that becomes negative suggests IgM (usually less clinically significant).
• CDC detects only complement-fixing antibodies; flow crossmatch detects non-fixing IgG too.
• Virtual crossmatch uses recipient SAB reactivity and donor HLA typing — no cell mixing.